480 related articles for article (PubMed ID: 13680840)
21. Cloning, expression, and selective inhibition of canine cyclooxygenase-1 and cyclooxygenase-2.
Gierse JK; Staten NR; Casperson GF; Koboldt CM; Trigg JS; Reitz BA; Pierce JL; Seibert K
Vet Ther; 2002; 3(3):270-80. PubMed ID: 12447834
[TBL] [Abstract][Full Text] [Related]
22. Novel cyclooxygenase-1 inhibitors discovered using affinity fingerprints.
Hsu N; Cai D; Damodaran K; Gomez RF; Keck JG; Laborde E; Lum RT; Macke TJ; Martin G; Schow SR; Simon RJ; Villar HO; Wick MM; Beroza P
J Med Chem; 2004 Sep; 47(20):4875-80. PubMed ID: 15369391
[TBL] [Abstract][Full Text] [Related]
23. Synthesis and effects on the COX-1 and COX-2 activity in human whole blood ex vivo of derivatives containing the [1]benzothienol-[3, 2-d]pyrimidin-4-one heterocyclic system.
Santagati A; Granata G; Marrazzo A; Santagati M
Arch Pharm (Weinheim); 2003 Sep; 336(9):429-35. PubMed ID: 14528491
[TBL] [Abstract][Full Text] [Related]
24. Effects of tanshinone I isolated from Salvia miltiorrhiza bunge on arachidonic acid metabolism and in vivo inflammatory responses.
Kim SY; Moon TC; Chang HW; Son KH; Kang SS; Kim HP
Phytother Res; 2002 Nov; 16(7):616-20. PubMed ID: 12410540
[TBL] [Abstract][Full Text] [Related]
25. COX-2 inhibition: not too hot, not too cold--(perhaps) just right?
Bakowsky V; Hanly JG
J Rheumatol; 2000 Dec; 27(12):2734-7. PubMed ID: 11128655
[No Abstract] [Full Text] [Related]
26. Effects of non-steroidal anti-inflammatory drugs on cyclo-oxygenase and lipoxygenase activity in whole blood from aspirin-sensitive asthmatics vs healthy donors.
Gray PA; Warner TD; Vojnovic I; Del Soldato P; Parikh A; Scadding GK; Mitchell JA
Br J Pharmacol; 2002 Dec; 137(7):1031-8. PubMed ID: 12429575
[TBL] [Abstract][Full Text] [Related]
27. COX-2 inhibitors--is there cause for concern?
Seibert K; Lefkowith J; Tripp C; Isakson P; Needleman P
Nat Med; 1999 Jun; 5(6):621-2. PubMed ID: 10371498
[No Abstract] [Full Text] [Related]
28. Design, synthesis, and biological evaluation of 6-substituted-3-(4-methanesulfonylphenyl)-4-phenylpyran-2-ones: a novel class of diarylheterocyclic selective cyclooxygenase-2 inhibitors.
Praveen Rao PN; Amini M; Li H; Habeeb AG; Knaus EE
J Med Chem; 2003 Nov; 46(23):4872-82. PubMed ID: 14584938
[TBL] [Abstract][Full Text] [Related]
29. (-)-Epiafzelechin: cyclooxygenase-1 inhibitor and anti-inflammatory agent from aerial parts of Celastrus orbiculatus.
Min KR; Hwang BY; Lim HS; Kang BS; Oh GJ; Lee J; Kang SH; Lee KS; Ro JS; Kim Y
Planta Med; 1999 Jun; 65(5):460-2. PubMed ID: 10418338
[TBL] [Abstract][Full Text] [Related]
30. Dual inhibition of cyclooxygenase-1 and 5-lipoxygenase by aerial part of Bupleurum fruticescens methanol extract.
Prieto JM; Giner RM; Recio MC; Máñez S; Ríos JL
Fitoterapia; 2004 Mar; 75(2):179-86. PubMed ID: 15030922
[TBL] [Abstract][Full Text] [Related]
31. Flavonoids and stilbenoids with COX-1 and COX-2 inhibitory activity from Dracaena loureiri.
Likhitwitayawuid K; Sawasdee K; Kirtikara K
Planta Med; 2002 Sep; 68(9):841-3. PubMed ID: 12357401
[TBL] [Abstract][Full Text] [Related]
32. [COX-1 and COX-2: functions and pharmacological effects].
Hinz B; Brune K
Pharm Unserer Zeit; 1999 Jan; 28(1):21-9. PubMed ID: 10078026
[No Abstract] [Full Text] [Related]
33. The future of NSAID therapy: selective COX-2 inhibitors.
Vane JR; Botting RM
Int J Clin Pract; 2000; 54(1):7-9. PubMed ID: 10750251
[No Abstract] [Full Text] [Related]
34. Development of a radiochemical cyclooxygenase-1 and -2 in vitro assay for identification of natural products as inhibitors of prostaglandin biosynthesis.
Noreen Y; Ringbom T; Perera P; Danielson H; Bohlin L
J Nat Prod; 1998 Jan; 61(1):2-7. PubMed ID: 9461646
[TBL] [Abstract][Full Text] [Related]
35. Design, synthesis, and biological evaluation of N-acetyl-2-(or 3-)carboxymethylbenzenesulfonamides as cyclooxygenase isozyme inhibitors.
Chen QH; Rao PN; Knaus EE
Bioorg Med Chem; 2005 Aug; 13(15):4694-703. PubMed ID: 15914011
[TBL] [Abstract][Full Text] [Related]
36. The discovery and function of COX-2.
Needleman P; Isakson PC
J Rheumatol Suppl; 1997 Jul; 49():6-8. PubMed ID: 9249644
[No Abstract] [Full Text] [Related]
37. [Specificity, action, indications and safety. Criteria for the use of COX-2 inhibitors].
Wigand R
Pharm Unserer Zeit; 2002; 31(2):190-8. PubMed ID: 11977455
[No Abstract] [Full Text] [Related]
38. Cyclooxygenase-2 inhibitors: promise or peril?
Mengle-Gaw LJ; Schwartz BD
Mediators Inflamm; 2002 Oct; 11(5):275-86. PubMed ID: 12467519
[TBL] [Abstract][Full Text] [Related]
39. Cyclooxygenase-3 (COX-3): filling in the gaps toward a COX continuum?
Warner TD; Mitchell JA
Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13371-3. PubMed ID: 12374850
[No Abstract] [Full Text] [Related]
40. Cyclooxygenase (COX) inhibitors: a comparative QSAR study.
Garg R; Kurup A; Mekapati SB; Hansch C
Chem Rev; 2003 Mar; 103(3):703-32. PubMed ID: 12630850
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
